217 related articles for article (PubMed ID: 10906221)
1. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.
Ramírez JC; Gherardi MM; Rodríguez D; Esteban M
J Virol; 2000 Aug; 74(16):7651-5. PubMed ID: 10906221
[TBL] [Abstract][Full Text] [Related]
2. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein.
Dallo S; Maa JS; Rodriguez JR; Rodriguez D; Esteban M
Virology; 1989 Nov; 173(1):323-9. PubMed ID: 2510402
[TBL] [Abstract][Full Text] [Related]
3. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
4. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.
Gómez CE; Rodríguez D; Rodríguez JR; Abaitua F; Duarte C; Esteban M
Vaccine; 2001 Dec; 20(5-6):961-71. PubMed ID: 11738764
[TBL] [Abstract][Full Text] [Related]
5. Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization.
Naito T; Kaneko Y; Kozbor D
J Gen Virol; 2007 Jan; 88(Pt 1):61-70. PubMed ID: 17170437
[TBL] [Abstract][Full Text] [Related]
6. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
7. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
[TBL] [Abstract][Full Text] [Related]
8. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.
Ramírez JC; Gherardi MM; Esteban M
J Virol; 2000 Jan; 74(2):923-33. PubMed ID: 10623755
[TBL] [Abstract][Full Text] [Related]
9. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
10. Enhanced CD8+ T cell response to HIV-1 env by combined immunization with influenza and vaccinia virus recombinants.
Gonzalo RM; Rodríguez D; García-Sastre A; Rodríguez JR; Palese P; Esteban M
Vaccine; 1999 Feb; 17(7-8):887-92. PubMed ID: 10067695
[TBL] [Abstract][Full Text] [Related]
11. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
Carroll MW; Overwijk WW; Chamberlain RS; Rosenberg SA; Moss B; Restifo NP
Vaccine; 1997 Mar; 15(4):387-94. PubMed ID: 9141209
[TBL] [Abstract][Full Text] [Related]
12. Characterization of an attenuated TE3L-deficient vaccinia virus Tian Tan strain.
Wang Y; Kan S; Du S; Qi Y; Wang J; Liu L; Ji H; He D; Wu N; Li C; Chi B; Li X; Jin N
Antiviral Res; 2012 Dec; 96(3):324-32. PubMed ID: 23084929
[TBL] [Abstract][Full Text] [Related]
13. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
14. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
[TBL] [Abstract][Full Text] [Related]
15. B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.
Viner KM; Girgis N; Kwak H; Isaacs SN
Virology; 2007 May; 361(2):356-63. PubMed ID: 17188733
[TBL] [Abstract][Full Text] [Related]
16. Comparison on virulence and immunogenicity of two recombinant vaccinia vaccines, Tian Tan and Guang9 strains, expressing the HIV-1 envelope gene.
Zhu R; Huang W; Wang W; Liu Q; Nie J; Meng S; Yu Y; Wang Y
PLoS One; 2012; 7(11):e48343. PubMed ID: 23139778
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide.
Gherardi MM; Ramírez JC; Esteban M
J Virol; 2000 Jul; 74(14):6278-86. PubMed ID: 10864637
[TBL] [Abstract][Full Text] [Related]
18. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.
Cooney EL; Collier AC; Greenberg PD; Coombs RW; Zarling J; Arditti DE; Hoffman MC; Hu SL; Corey L
Lancet; 1991 Mar; 337(8741):567-72. PubMed ID: 1671940
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.
Ober BT; Brühl P; Schmidt M; Wieser V; Gritschenberger W; Coulibaly S; Savidis-Dacho H; Gerencer M; Falkner FG
J Virol; 2002 Aug; 76(15):7713-23. PubMed ID: 12097585
[TBL] [Abstract][Full Text] [Related]
20. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
